The Accelerator Corporation out of Seattle is birthing a new biotech baby today called Rodeo Therapeutics, which will start out with a $5.9 million A round and an ambitious goal to develop molecules that can amp up tissue regeneration.
Rodeo is getting started with three scientific godfathers: Case Western’s Sanford Markowitz, Stanton Gerson from the National Center for Regenerative Medicine and Joseph Ready out of UT Southwestern.
And while it’s launching with a small round, it has some big name backers: AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly, Johnson & Johnson Innovation, Watson Fund, WRF Capital and WuXi AppTec.
“The ability to stimulate the body’s natural processes for tissue regeneration and repair has broad therapeutic potential in disease settings such as ulcerative colitis and in hemopoietic recovery following bone marrow transplantation,” Markowitz said in a statement. “Rodeo Therapeutics is focused on developing small-molecule therapies that stimulate these processes and enable new approaches to address serious medical conditions that today have a substantial unmet medical need.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription